News archives

Phytopharm announces results of interim data review

20 January 2005

Preliminary results of completed study expected fourth quarter 2005

Phytopharm and Unilever enter into a Licence and Joint Development Agreement for Hoodia gordonii Extract

15 December 2004

Agreement includes provisions for substantial milestone payments, stage payments and royalties

Preliminary results for the year ended 31 August 2004

3 December 2004

Phytopharm plc has announced their preliminary results for the year ended 31 August 2004

To present at the sixth annual Rodman and Renshaw Techvest Healthcare Conference

22 November 2004

Phytopharm plc (LSE: PYM; NASDAQ: PHYOF.PK) today announced that Richard Dixey, its chief executive officer, will present at the Sixth Annual Rodman and Renshaw Techvest Healthcare Conference on Tuesday, October 26, 2004 at 9:45 a.m. EDT. The conference will be held from October 26-28 at the Waldorf Astoria Hotel in New York City.

Fast Track designation granted by the FDA for ALS drug candidate Myogane™

9 November 2004

Phytopharm plc (PYM: London Stock Exchange; NASDAQ: PHYOF) (”Phytopharm”) announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate PYM50018 (MyoganeT) for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease).

Appointment of Broker

2 November 2004

Phytopharm plc announces that it has appointed Canaccord Capital (Europe) Ltd as sole broker to the Company with immediate effect.

Announces its Completion of a Level-I ADR Program and its Intention to List on NASDAQ

18 August 2004

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the establishment of a Level-I American Depositary Receipt (ADR) program and its intention to list on NASDAQ. The Level-I program represents the first step in listing Phytopharm’s securities on NASDAQ. The Bank of New York has been appointed as the depositary bank for the Level-I ADR program and the New York based investment bank, Global Markets Capital Group, LLC will manage the listing process.

Orphan drug designation granted by the FDA for drug candidate to treat ALS

26 July 2004

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate PYM50018 for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). Phytopharm has recently registered the trademark Myogane™ as a name for this product.

Launch of second product in UK

16 June 2004

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the UK launch of Zanthofen™ (PYM50014), its plant based product for the maintenance of canine joint mobility. Zanthofen™ will be available to veterinarians across the UK and launched in collaboration with Genitrix Ltd, one of the UK’s fastest growing veterinary product companies.

Interim results for the period to 29 February 2004

5 May 2004

Download PDF (273KB)